- Company
- Daewon’s Pelubi enters Indonesia with a KRW 4 bil deal
- by Chon, Seung-Hyun Sep 26, 2023 05:49am
- On the 25th, Daewon Pharmaceutical announced that its nonsteroidal anti-inflammatory drug, ‘Pelubi CR Tab’ has entered the Indonesian market. Daewon Pharmaceutical signed an exclusive export agreement with its Indonesian partner, PT. Interbat Pharmaceutical Industry, to export its finished Pelubi CR Tablet products to Indonesia. The 5-y
- Company
- Luxturna can be prescribed at general hospitals
- by Eo, Yun-Ho Sep 26, 2023 05:49am
- Luxturna, a one-shot retina treatment, can be prescribed at general hospitals. According to related industries, Luxturna, a treatment for Inherited Retinal Dystrophy, has passed the drug committee of medical institutions such as Seoul National University Hospital. Luxturna is currently in the process of registering for insurance benefits a
- Company
- Roche’s Rozlytrek lands in tertiary hospitals in Korea
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- The tumor-agnostic anticancer drug ‘Rozlytrek’ may now be prescribed in 5 tertiary hospitals in Korea. According to industry sources, Roche Korea’s NTRK(Neurotrophic tyrosine receptor kinase) inhibitor Rozlytrek (entrectinib)’ has passed review of drug committees (DCs) at the Big 5 tertiary hospitals in Korea, - Samsung Medical Center
- Company
- RET-targeted anticancer drugs fail reimb…no promise
- by Eo, Yun-Ho Sep 25, 2023 05:34am
- With RET-targeted anticancer drugs failing to receive reimbursement, patients are now left to wait indefinitely for coverage of their drugs. Lilly Korea's RET inhibitor Retevmo (selpercatinib) failed to be listed for reimbursement last month due to the final breakdown in drug price negotiations with the National Health Insurance Service.
- Company
- Boryung develops 4-drug kanarb combo… increases lineup
- by Chon, Seung-Hyun Sep 22, 2023 05:42am
- On the 20th, Boryung Pharmaceutical announced that the Ministry of Food and Drug Safety has approved the Phase III clinical trial plan (investigational new drug, IND) for ‘BR1018,’ its incrementally modified drug candidate for hypertension and dyslipidemia. BR1018 is a four-drug combination that combined amlodipine, atorvastatin, and e
- Company
- Next-gen asthma drug Tezspire to soon be introduced to KOR
- by Eo, Yun-Ho Sep 22, 2023 05:41am
- The next-generation drug for severe asthma, ‘Tezpire' is soon expected to enter the Korean market. According to industry sources, AstraZeneca Korea has submitted an application for the approval of ‘Tezspire (tezepelumab)’ in H2 to the Ministry of Food and Drug Safety and is receiving its final review. Whether AstraZeneca will be abl
- Company
- A new drug for optic shylomyelitis is necessary
- by Eo, Yun-Ho Sep 20, 2023 05:35am
- Off labels refer to the act of prescribing a medicine for an indication other than a use approved by the Ministry of Food and Drug Safety. In general, the use of the drug has been determined by the health authorities, and the question may arise as to why it is necessary. However, there is an area of disease where this Off label prescri
- Company
- Pricing & reimbursement specialist introduced as a new job
- by Kang, Shin-Kook Sep 20, 2023 05:35am
- New occupations such as ‘Pricing & reimbursement specialist’ and ‘biopharmaceutical candidate substance researcher’ were added as new occupations in the bio and pharmaceutical industry. On the 19th, the Korea Employment Information Service (President Young-Jun Kim) announced it had added 156 new occupations in the fields of life scien
- Company
- No news after passing the cancer screening
- by Eo, Yun-Ho Sep 20, 2023 05:35am
- Xospata's progress in expanding insurance benefits, which seemed to be going smoothly, appears to have stopped. According to related industries, Astellas Korea Pharmaceutical's FLT3 mutation-positive recurrence or Acute Myeloid Leukemia treatment Xospata was not submitted during the three HIRA Pharmaceutical Reimbursement Evaluation Commi
- Company
- Korea United Pharm signs export agreement with Vietnam TAK
- by Nho, Byung Chul Sep 19, 2023 05:42am
- On the 18th, Korea United Pharm (CEO Duk-Young Kang) attended the 2023 Global Bio& Pharma Plaza (GBPP) 2023 and forged close relationships with over 20 overseas buyers. The company announced that it had accelerated its global expansion by signing export contracts for Vietnam and the Philippines on the day of the event. Korea United Phar
